VINC Stock Overview
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Vincerx Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.06 |
52 Week High | US$9.37 |
52 Week Low | US$0.61 |
Beta | 0.76 |
1 Month Change | 24.94% |
3 Month Change | 328.81% |
1 Year Change | 419.72% |
3 Year Change | -73.69% |
5 Year Change | n/a |
Change since IPO | -45.88% |
Recent News & Updates
Recent updates
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Jul 18Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Mar 30Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?
Sep 22Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?
Jun 24Vincerx Pharma doses first patient in early-stage VIP152 cancer study
Jun 03Shareholder Returns
VINC | US Biotechs | US Market | |
---|---|---|---|
7D | -7.2% | 0.9% | 0.4% |
1Y | 419.7% | 10.3% | 28.8% |
Return vs Industry: VINC exceeded the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: VINC exceeded the US Market which returned 28.8% over the past year.
Price Volatility
VINC volatility | |
---|---|
VINC Average Weekly Movement | 29.8% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VINC's share price has been volatile over the past 3 months.
Volatility Over Time: VINC's weekly volatility has increased from 19% to 30% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | 41 | Ahmed Hamdy | https://vincerx.com |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company’s preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies.
Vincerx Pharma, Inc. Fundamentals Summary
VINC fundamental statistics | |
---|---|
Market cap | US$129.57m |
Earnings (TTM) | -US$48.85m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs VINC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VINC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$48.85m |
Earnings | -US$48.85m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.28 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did VINC perform over the long term?
See historical performance and comparison